Indian pharmaceutical companies face significant market volatility following Trump's announcement of aggressive tariff policies on generic medications. The proposed framework introduces a two-year grace period before implementing substantial duties starting 2028, creating both challenges and opportunities for industry leaders like Sun Pharma and Cipla. This policy shift could reshape global drug pricing dynamics and impact India's dominant position in generic medicine exports to the United States.

Summary auto-generated by AI from the original publisher's content. Editorial standards.